The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Identifying Unintentional Effects Of Medication Using Statistical Genetics Analyses Of Large-scale Genetic And Genomic Data
Funder
National Health and Medical Research Council
Funding Amount
$251,441.00
Summary
An increasing number of studies have highlighted unknown adverse effects of medication, for example, use of statins to lower cholesterol with increased risk of type 2 diabetes. The gold standard approach to confirm these effects is randomised control trials, which may not always be feasible or ethical, and are very expensive. This project aims to apply innovative statistical genetics approaches to (genetic and genomic) 'big-data' to predict unknown effects of commonly prescribed medications.
Better Statistical Methods To Discover Host Genetic Factors In Symptom Response To SARS-CoV-2 Infection
Funder
National Health and Medical Research Council
Funding Amount
$290,137.00
Summary
The COVID-19 pandemic has infected >5 million people worldwide. While the majority of infected individuals recover within a few weeks of infection, others develop severe forms, that in some cases prove fatal. To date, the causes of differences in symptom response are unknown. In this proposal, we seek to discover genetic factors that can contribute to explaining these differences. Our findings have the potential to inform the design and analysis of clinical trials for vaccines and treatments.
New Therapeutic Approaches For Genetic Skeletal Disorders
Funder
National Health and Medical Research Council
Funding Amount
$961,150.00
Summary
Genetic skeletal disorders are a significant disease burden with limited therapeutic options. We will use mouse models of cartilage and bone disorders and human induced pluripotent stem cell derived bone and cartilage 'disease in a dish' models to test repurposed FDA-approved drugs and new drug candidates as novel therapeutic strategies.
Sudden cardiac death (SCD) is a devastating consequence of a number of heart diseases. Underlying causes include inherited heart muscle problems (cardiomyopathies), with no cause found in 40%. Our study will investigate the role of 'concealed cardiomyopathy' cases, i.e. those with a SCD event with no evidence of heart disease, but carry errors in heart genes. Our findings will translate rapidly into more targeted clinical and genetic evaluation of families with the ultimate goal to prevent SCD.
ARX- A Hub Gene For A Common Biological Pathway In Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$707,974.00
Summary
Schizophrenia is a severe psychiatric disorder with no cure. I have identified that some people with schizophrenia show variations to a gene called ARX. This project will use preclinical mouse models to explore how variations to the Arx gene affect brain molecules, networks of cells and behavioural outcomes. This biological pathway will provide the framework for the identification of new molecules to target therapeutically to modify the biological course of schizophrenia and improve outcomes.